EXEL is the ticker symbol for EXELIXIS, INC., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks EXEL with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is EXEL a good stock to buy?

13F Pro's AI ranking engine scores EXEL at 76.1/100, ranked #83 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for EXEL is available at https://13fpro.ai/company/EXEL. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source EXEL data?

All EXELIXIS, INC. fundamentals and ownership data come directly from SEC EDGAR. EXELIXIS, INC. files with the SEC under CIK 939767. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

EXELIXIS, INC. EXEL

NasdaqLarge CapHealthcare

13F Pro quality score

Rank #83 of 2,925TOP 5%

Why it scores 76 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$628.69M

Quarter to Jul 3

Net income

$212.05M

Quarter to Jul 3

Free cash flow

$300.93M

Quarter to Jul 3

Operating margin

39.5%

Quarter to Jul 3

Top Institutional Holders

as of Q2 2026

$14.09B total

BlackRock, Inc.

$1.58B-5.6%

FARALLON CAPITAL MANAGEMENT LLC

$732.79M+2.7%

RENAISSANCE TECHNOLOGIES LLC

$730.62M-2.2%

VANGUARD PORTFOLIO MANAGEMENT LLC

$655.27M-0.3%

AQR CAPITAL MANAGEMENT LLC

$598.60M-15.8%

VANGUARD CAPITAL MANAGEMENT LLC

$595.84M-2.7%

STATE STREET CORP

$542.47M-3.2%

FULLER & THALER ASSET MANAGEMENT, INC.

$485.85M+4.5%

LSV ASSET MANAGEMENT

$443.25M+5.2%

GEODE CAPITAL MANAGEMENT, LLC

$416.32M-1.9%

D. E. Shaw & Co., Inc.

$302.07M+54.1%

MORGAN STANLEY

$245.92M+8.2%

Invesco Ltd.

$244.61M+4.2%

DIMENSIONAL FUND ADVISORS LP

$240.85M+3.0%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$237.55M-9.7%

TWO SIGMA INVESTMENTS, LP

$229.06M+90.8%

ASSETMARK, INC

$186.83M+1.3%

Nuveen, LLC

$178.30M-13.4%

UBS Group AG

$172.36M+32.4%

Stephens Investment Management Group LLC

$147.45M+7.3%

GOLDMAN SACHS GROUP INC

$146.39M+27.0%

NORGES BANK

$146.30M--

FIRST TRUST ADVISORS LP

$138.38M+0.3%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$123.07M-2.4%

BANK OF AMERICA CORP /DE/

$116.95M+30.7%

See all 760 institutional holders →

What's Driving EXEL's Business? Latest 10-Q Breakdown

26/26 datapoints verified

AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenues rose 11% to $628.7M as CABOMETYX net product revenues grew 10% to $570.6M on 6% unit growth, lifting net income to $212.1M ($0.82 diluted).

Biggest Revenue Drivers

Net product revenues$573.0M+10% YoY

6% increase in CABOMETYX units sold plus a 4% increase in average net selling price

License revenues$59.8M+21% YoY

Increases in Ipsen's net sales of cabozantinib outside the U.S. and Japan; Ipsen royalties were $50.5M

Biggest Revenue Drivers

Total revenue: $628.7M+11% YoY

Net product revenues$573.0M+10% YoY

6% increase in CABOMETYX units sold plus a 4% increase in average net selling price

Within Net product revenues

CABOMETYX$570.6M+10% YoY

Continuing demand in combination with nivolumab in first-line advanced RCC and demand in previously treated advanced NET

License revenues$59.8M+21% YoY

Increases in Ipsen's net sales of cabozantinib outside the U.S. and Japan; Ipsen royalties were $50.5M

Collaboration services revenues-$4.1M+293% YoY

Lower development cost reimbursements and higher 3% royalties paid to Royalty Pharma on partner sales

Largest Expense Items

Research and development$212.0M+6% YoY

Higher clinical trial costs for zanzalintinib, XB371 and XB628, manufacturing and license costs, offset by lower personnel expense

Selling, general and administrative$147.6M+9% YoY

Increased marketing for zanzalintinib pre-launch activities and higher personnel expenses

Cost of goods sold$20.7M+6% YoY

Higher royalties from increased U.S. CABOMETYX sales

Margins: Gross margin held at 96%, unchanged from the prior-year quarter, and management projects gross margin will not change significantly during the remainder of 2026.

Watch Items from the Filing

Generic/505(b)(2) filers MSN, Azurity, Handa, Accord and Almatica challenge CABOMETYX patents; consolidated trial set November 2, 2026, and FDA gave Handa tentative approval July 29, 2026.
Five customers each exceed 10% of revenue: McKesson 21%, Cencora 20%, CVS 15%, Accredo 10%, Cardinal Health 10%.
Zanzalintinib NDA in colorectal cancer has a PDUFA date of December 3, 2026; the NLM subgroup endpoint missed statistical significance (HR 0.83, P=0.1185).
Repurchased 20.2M shares for $902.2M under buyback programs; cash and marketable securities fell to $1.4B from $1.7B at December 31, 2025.
Future in-licensing obligations include up to $441.5M development, $278.0M regulatory and $2.5B commercial milestone payments.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/EXEL

Earnings Per Share

13fpro.ai/company/EXEL

Loading ratio trend…

EXELIXIS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$2.3B	$782.6M	37.6%
FY 2024	10-K	$2.2B	$521.3M	27.9%
FY 2023	10-K	$1.8B	$207.8M	9.3%
FY 2022	10-K	$1.6B	$182.3M	12.5%
FY 2021	10-K	$1.4B	$231.1M	20.0%
FY 2020	10-K	$987.5M	$111.8M	11.1%

About EXELIXIS, INC. (EXEL): stock profile, AI score and financials

EXELIXIS, INC. (EXEL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EXEL at 76.1/100 on a composite quality score built from its SEC filings, placing it at rank #83 of 2,925 stocks — the top 5% of the AI-ranked universe. EXEL scores in the top quartile across balance sheet strength (98.6), profitability (95.2), free cash flow (94.6). Shareholder dilution risk is elevated at 24.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), EXELIXIS, INC. reports quarterly revenue of $628.7M, net income of $212.1M, an operating margin of 39.5%. Top institutional holders of EXEL by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. EXEL trades on the Nasdaq exchange and files with the SEC under CIK 939767. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EXEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXELIXIS, INC. directly from SEC EDGAR.

Financials through the period ended Jul 3, 2026SEC EDGAR: CIK 939767 →

EXELIXIS, INC. EXEL

Top Institutional Holders

What's Driving EXEL's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

EXEL key financials by period

EXEL insiders

About EXELIXIS, INC. (EXEL): stock profile, AI score and financials

EXELIXIS, INC. EXEL

Top Institutional Holders

What's Driving EXEL's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

EXEL key financials by period

Companies similar to EXEL

EXEL insiders

About EXELIXIS, INC. (EXEL): stock profile, AI score and financials